TITLE:
Gastro Intestinal Stromal Tumor: State of the Art through Our Experience of 64 Cases and a Literature Review
AUTHORS:
Saad Slaiki, Hicham El Bouhaddouti, Abdelmalek Ousadden, Khalid Ait Taleb, El Bachir Benjelloun
KEYWORDS:
Stromal Tumor, Imatinib, Surgery, GIST
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.5,
May
8,
2020
ABSTRACT: Gastrointestinal
stromal tumors are rare. They are a subject of controversy. We have reported 64 cases
of gastrointestinal stromal tumor diagnosed in the surgery department of CHU
Hassan II of FES between January 2014 and December 2018. The study involved 64
patients (34 men and 30 women) with an average age of 56. The circumstances of
findings were dominated by abdominal pain (48 cases), vomiting 16 case followed
by transit disorder with 9 cases. The tumor locations were mainly the stomach
(n = 31), the small intestine (n = 28), the duodenum (n = 3), and the colon (n
= 2). Ultrasound, endoscopy and CT were the main additional tests to detect
tumor syndrome. 55 patients were treated by complete surgical excision. Tumor size ranged from 4cm to 18cm.
Histologically, the spindle cell type was predominant in 88.91% of cases; epithelioid type was present in 7.81% of cases,
while the mixed type was found in 3.6%. The analysis of the expression of CD 117 marker was
present in 95.31%, while immunostaining with this marker returned negative in 3
cases; i.e. 5% whose c-kit was positive. Imatinib was indicated
in 44 patients (63.60%), with 9 indications for metastatic tumor. As a neoadjuvant, imatinib was indicated in 5 patients, with remission in
28 patients (50.9%), stabilization in 4 patients (7.2%), 2 cases of tumor
recurrence and 7 cases of death.